EGFR mutations play an important role in the development and progression of non-small cell lung cancer (NSCLC) This article compares the effectiveness of afatinib and osimertinib in patients with NSCLC who harbored uncommon EGFR mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.